ICER Review of New Rescue Medications
In November, I wrote about an opportunity to advocate for yourself and others in the article Advocate by Sharing Your Story with ICER. Thank you to over 100 people who submitted comments to ICER (Institute for Clinical & Economic Review). This week will wrap up the final stage of ICER’s economic assessment of two new classes of migraine rescue medications (gepants and ditans).
Facebook Live event
On Wednesday, January 22nd, 2020, Migraine.com will be hosting a Facebook Live event in partnership with the Headache & Migraine Policy Forum from 12:30 pm to 1:30 pm central time (or 1:30 pm to 1:30 pm eastern time).
This event will address the need for safe, effective and affordable treatments. It's our chance to have a patient-centered discussion surrounding access and insurance coverage issues for these new migraine rescue medications.
How does ICER's report impact your insurance coverage?
ICER’s final report will influence insurance companies’ decisions when determining if they will cover these new medicines, which tier the medicines will be placed on in your plan’s formulary, and what types of prior authorization or step therapy will be required. All of this will heavily impact the access migraine patients have to this new class of rescue medications.
ICER needs to understand how painful and disabling migraine disease is, how limited the effectiveness of current treatments are, and how vast the need is for patients to be able to access new rescue migraine medicines.
We want to hear from you!
Do you have questions you'd like the panel to address? Share them in the comments section below. You'll also have a chance to ask questions during the FB Live. Please join us on Wednesday, January 22 at 12:30pm central time on Migraine.com's Facebook page.
Have you taken our Migraine In America Survey yet?